GALNS and mucopolysaccharidosis type 4A: As gene therapy for MPS IVA, Sawamoto et al. (2020) administered AAV8 vector expressing different forms of human GALNS, under a liver-specific promoter, intravenously into 4-week-old MPS IVA mice.